Danske Bank’s Revance Therapeutics, Inc. RVNC Stock Holding History

Danske Bank’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-600	Closed	-$1.82K	–	1492
2024 Q4	$1.82K	Sell	600 -600	-50%	-$2.61K	﹤0.01%	1280
2024 Q3	$6.23K	Sell	1,200 -11,000	-90%	-$54.7K	﹤0.01%	1443
2024 Q2	$31.4K	Buy	+12,200	New	+$41.7K	﹤0.01%	1018

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Danske Bank's RVNC Position: Q1 2025 in Review

Danske Bank sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 600 shares — an estimated $1.82K sold.

Danske Bank first reported a position in RVNC in Q2 2024 and held it in 3 quarters. The position peaked at $31.4K in Q2 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Danske Bank reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Danske Bank sold 600 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.82K.
Danske Bank first reported a position in Revance Therapeutics, Inc. in Q2 2024 and held it in 3 quarters.
Danske Bank's Revance Therapeutics, Inc. position peaked at $31.4K in Q2 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Danske Bank's 13F filing for Q1 2025, filed 18 Dec 2025.